Researchers at the University of Michigan have described what they said is the first microbial-metabolite-based oral drug designed to improve stem-like CD8+ T cell immunity against tumors, demonstrating efficacy across five preclinical cancer models including one resistant to immune checkpoint blockade, according to a study published August 10, 2026 in Nature Nanotechnology.
The work, led by James J. Moon at Michigan's Rogel Cancer Center and Biointerfaces Institute, addresses an important limitation of checkpoint inhibitor therapy: responses to anti-PD-1 treatment depend in part on stem-like progenitor CD8+ T cells capable of replenishing exhausted effector populations, creating interest in strategies that preserve or expand this population. The study provides a mechanistic link between a specific gut microbial metabolite and T cell stemness, and packages that biology into an orally deliverable prodrug nano-emulsion.
The researchers identified 3,4-dihydroxybenzoic acid (DHB, also known as protocatechuic acid) through a screen of gut microbial metabolites. DHB depleted intracellular glutathione and suppressed Akt-mTORC1-Myc signaling, reducing glycolysis and shifting CD8+ T cells toward a metabolically quiescent, stem-like state while preserving their capacity to mount an immune response.
Free DHB is highly hydrophilic, with a plasma half-life of approximately 0.4 hours and limited systemic exposure after oral dosing. To overcome this, the researchers developed Prodrug 201, which achieved a 9.72-fold improvement in oral bioavailability and extended plasma half-life to approximately 4.1 hours in rats, supporting once-daily oral dosing.
In the CT26 colorectal implanted tumor model, Prodrug 201 monotherapy produced significant tumor growth inhibition versus vehicle, and combination with anti-PD-1 antibody produced superior tumor control over either monotherapy alone, with complete or near-complete responses observed in the combination arm. In the NOOC1 squamous cell carcinoma model, which was characterized as immune checkpoint blockade (ICB)-resistant, Prodrug 201 sensitized tumors to anti-PD-1, with monotherapy arms showing limited activity. Efficacy was also demonstrated across additional spontaneous tumor models, while no significant weight loss or overt adverse effects were reported across treatment groups.